Brown, David M.

Ranibizumab for Neovascular Age-Related Macular Degeneration

Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 5,886

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 3,522

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration

Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 2,485

Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study

Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 1,318

HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration

Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., Gomes, A. V., Warburton, J., Weichselberger, A., & Holz, F. G. (2020) · Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 931

Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1

Regillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 858

Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration

Schmidt-Erfurth, U., Kaiser, P. K., Korobelnik, J.-F., Brown, D. M., Chong, V., Nguyen, Q. D., Ho, A. C., Ogura, Y., Simader, C., Jaffe, G. J., et al. (2014) · Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 822

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Heier, J. S., Khanani, A. M., Quezada Ruiz, C., Basu, K., Ferrone, P. J., Brittain, C., Figueroa, M. S., Lin, H., Holz, F. G., Patel, V., et al. (2022) · The Lancet

Retinal Diseases and TreatmentsOcular Diseases and Behçet’s Syndrome

Cited by 785

Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials

Heier, J. S., Lad, E. M., Holz, F. G., Rosenfeld, P. J., Guymer, R. H., Boyer, D., Grossi, F., Baumal, C. R., Korobelnik, J.-F., Slakter, J. S., et al. (2023) · The Lancet

Retinal Diseases and TreatmentsOcular Diseases and Behçet’s Syndrome

Cited by 520

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration

Busbee, B. G., Ho, A. C., Brown, D. M., Heier, J. S., Suñer, I. J., Li, Z., Rubio, R. G., & Lai, P. (2013) · Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 500

Ranibizumab for Predominantly Classic Neovascular Age-related Macular Degeneration: Subgroup Analysis of First-year ANCHOR Results

Kaiser, P. K., Brown, D. M., Zhang, K., Hudson, H. L., Holz, F. G., Shapiro, H., Schneider, S., & Acharya, N. R. (2007) · American Journal of Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 361

Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study

Campochiaro, P. A., Avery, R., Brown, D. M., Heier, J. S., Ho, A. C., Huddleston, S. M., Jaffe, G. J., Khanani, A. M., Pakola, S., Pieramici, D. J., et al. (2024) · The Lancet

Retinal Diseases and TreatmentsRetinal Development and Disorders

Cited by 135

Super-dose Anti-VEGF (SAVE) Trial: 2.0 mg Intravitreal Ranibizumab for Recalcitrant Neovascular Macular Degeneration–Primary End Point

Brown, D. M., Chen, E., Mariani, A., & Major, J. C. (2013) · Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 90

A randomized controlled trial of OPT-302, a VEGF-C/D inhibitor for neovascular age-related macular degeneration

Jackson, T. L., Slakter, J., Buyse, M., Wang, K., Dugel, P. U., Wykoff, C. C., Boyer, D. S., Gerometta, M., Baldwin, M. E., Price, C. F., et al. (2023) · Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 55

Outcomes of Eyes with Lesions Composed of >50% Blood in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)

Altaweel, M. M., Daniel, E., Martin, D. F., Mittra, R. A., Grunwald, J. E., Lai, M. M., Melamud, A., Morse, L. S., Huang, J., Ferris, F. L., et al. (2015) · Ophthalmology

Retinal Diseases and TreatmentsRetinal Imaging and Analysis

Cited by 51

Current best clinical practices—management of neovascular AMD

Brown, D., Heier, J. S., Boyer, D. S., Freund, K. B., Kaiser, P., Kim, J. E., & Sarraf, D. (2017) · Journal of VitreoRetinal Diseases

Retinal Diseases and TreatmentsOcular Diseases and Behçet’s Syndrome

Cited by 23